JP2024519496A5 - - Google Patents
Info
- Publication number
- JP2024519496A5 JP2024519496A5 JP2023567962A JP2023567962A JP2024519496A5 JP 2024519496 A5 JP2024519496 A5 JP 2024519496A5 JP 2023567962 A JP2023567962 A JP 2023567962A JP 2023567962 A JP2023567962 A JP 2023567962A JP 2024519496 A5 JP2024519496 A5 JP 2024519496A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- optionally substituted
- monocyclic
- alkynyl
- alkenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163184439P | 2021-05-05 | 2021-05-05 | |
| US63/184,439 | 2021-05-05 | ||
| PCT/US2022/027888 WO2022235945A1 (en) | 2021-05-05 | 2022-05-05 | Compounds for targeting degradation of bruton's tyrosine kinase |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024519496A JP2024519496A (ja) | 2024-05-14 |
| JP2024519496A5 true JP2024519496A5 (enExample) | 2025-05-14 |
Family
ID=82115630
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023567962A Pending JP2024519496A (ja) | 2021-05-05 | 2022-05-05 | ブルトンのチロシンキナーゼの分解を標的化するための化合物 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20240287076A1 (enExample) |
| EP (1) | EP4333899A1 (enExample) |
| JP (1) | JP2024519496A (enExample) |
| KR (1) | KR20240017814A (enExample) |
| CN (1) | CN117580592A (enExample) |
| AR (1) | AR125768A1 (enExample) |
| AU (1) | AU2022268977A1 (enExample) |
| BR (1) | BR112023023065A2 (enExample) |
| CA (1) | CA3217417A1 (enExample) |
| CL (1) | CL2023003258A1 (enExample) |
| CO (1) | CO2023016743A2 (enExample) |
| IL (1) | IL308219A (enExample) |
| JO (1) | JOP20230274A1 (enExample) |
| MX (1) | MX2023013046A (enExample) |
| TW (1) | TW202309039A (enExample) |
| UY (1) | UY39756A (enExample) |
| WO (1) | WO2022235945A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES3060629T3 (en) * | 2019-10-30 | 2026-03-27 | Biogen Ma Inc | Condensed bi-heterocycles as inhibiting agents for bruton's tyrosine kinase |
| MX2022005359A (es) | 2019-11-04 | 2022-06-02 | Revolution Medicines Inc | Inhibidores de ras. |
| IL301298A (en) | 2020-09-15 | 2023-05-01 | Revolution Medicines Inc | Indole derivatives as RAS inhibitors in cancer therapy |
| US12115154B2 (en) | 2020-12-16 | 2024-10-15 | Srx Cardio, Llc | Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) |
| JP7805983B2 (ja) | 2022-03-22 | 2026-01-26 | アッヴィ・インコーポレイテッド | ブルトン型チロシンキナーゼを分解するためのピリミジン |
| KR20250020448A (ko) | 2022-06-02 | 2025-02-11 | 시젱 하이스코 파마수티칼 씨오., 엘티디. | Bcl6을 억제하거나 분해하는 화합물 및 의약학에서의 응용 |
| KR20250135228A (ko) | 2023-01-09 | 2025-09-12 | 몬테 로사 테라퓨틱스 아게 | Vav1의 표적 분해 |
| WO2024245443A1 (zh) * | 2023-06-01 | 2024-12-05 | 标新生物医药科技(上海)有限公司 | 基于氧代异吲哚啉基取代的四氢嘧啶二酮的化合物及其应用 |
| JP2026524477A (ja) | 2023-06-30 | 2026-07-22 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｋｒａｓの分解のためのヘテロ二官能性化合物 |
| CN122206684A (zh) | 2023-06-30 | 2026-06-12 | 默克专利有限公司 | 用于kras蛋白降解的异双功能化合物 |
| TW202510854A (zh) | 2023-08-03 | 2025-03-16 | 大陸商西藏海思科製藥有限公司 | 多環並環btk降解劑及其在醫藥上的應用 |
| EP4763845A1 (en) | 2023-08-17 | 2026-06-24 | Haisco Pharmaceutical Group Co., Ltd. | Cyano aromatic ring derivative and pharmaceutical use thereof |
| US20260028345A1 (en) | 2024-07-26 | 2026-01-29 | Ascentage Pharma (Suzhou) Co., Ltd. | Btk degrader and use thereof |
| WO2026021570A1 (en) * | 2024-07-26 | 2026-01-29 | Ascentage Pharma (Suzhou) Co., Ltd. | Btk degrader and use thereof |
| WO2026078542A1 (en) * | 2024-10-07 | 2026-04-16 | Dana-Farber Cancer Institute, Inc. | Janus kinase 2 degraders |
| US20260146050A1 (en) | 2024-11-27 | 2026-05-28 | Boehringer Ingelheim International Gmbh | Kras degrading compounds comprising spirocyclic annulated 2 amino-3-cyano thiophenes |
| WO2026136866A1 (en) | 2024-12-20 | 2026-06-25 | Prelude Therapeutics Incorporated | Kat6 targeting compounds |
| WO2026139448A1 (en) | 2024-12-23 | 2026-07-02 | Merck Patent Gmbh | Heterobifunctional compounds for the degradation of kras protein |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| EP2548877A1 (en) * | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
| EP4649963A3 (en) | 2014-04-14 | 2026-05-13 | Arvinas Operations, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| JP6815318B2 (ja) | 2014-12-23 | 2021-01-20 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | 二官能性分子によって標的化タンパク質分解を誘導する方法 |
| JP6817962B2 (ja) | 2015-01-20 | 2021-01-20 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | ターゲティングされたアンドロゲン受容体分解のための化合物および方法 |
| AU2016232705C1 (en) | 2015-03-18 | 2021-06-17 | Arvinas, Inc. | Compounds and methods for the enhanced degradation of targeted proteins |
| CA2988414C (en) | 2015-06-04 | 2023-09-26 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| WO2016197114A1 (en) | 2015-06-05 | 2016-12-08 | Arvinas, Inc. | Tank-binding kinase-1 protacs and associated methods of use |
| WO2017007612A1 (en) | 2015-07-07 | 2017-01-12 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| EP3319944A4 (en) | 2015-07-10 | 2019-04-24 | Arvinas, Inc. | MDM2-BASED MODULATORS OF PROTEOLYSIS AND RELATED USE METHODS |
| CA2988436A1 (en) | 2015-07-13 | 2017-01-19 | Arvinas, Inc. | Alanine-based modulators of proteolysis and associated methods of use |
| EP3337476A4 (en) | 2015-08-19 | 2019-09-04 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| GB201516243D0 (en) | 2015-09-14 | 2015-10-28 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| US20170281784A1 (en) | 2016-04-05 | 2017-10-05 | Arvinas, Inc. | Protein-protein interaction inducing technology |
| AU2017246452C1 (en) | 2016-04-06 | 2021-06-03 | The Regents Of The University Of Michigan | MDM2 protein degraders |
| AU2017250076B2 (en) | 2016-04-12 | 2021-07-22 | The Regents Of The University Of Michigan | Bet protein degraders |
| CN121974842A (zh) | 2016-05-10 | 2026-05-05 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| CN109562113A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的螺环降解决定子体 |
| WO2017197056A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Bromodomain targeting degronimers for target protein degradation |
| WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
| CN109562107A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的杂环降解决定子体 |
| EP3512842B1 (en) | 2016-09-15 | 2024-01-17 | Arvinas, Inc. | Indole derivatives as estrogen receptor degraders |
| SI3526202T1 (sl) | 2016-10-11 | 2025-04-30 | Arvinas Operations, Inc. | Spojine in postopki za ciljno razgradnjo androgenskih receptorjev |
| MX2019005007A (es) | 2016-11-01 | 2019-07-18 | Arvinas Inc | Protac dirigidos a la proteína tau y métodos asociados de uso. |
| IL266842B (en) | 2016-12-01 | 2022-09-01 | Arvinas Operations Inc | History of tetrahydronaphthalene and tetrahydroisoquinoline as estrogen receptor antagonists |
| CN110753693A (zh) | 2016-12-23 | 2020-02-04 | 阿尔维纳斯运营股份有限公司 | Egfr蛋白水解靶向嵌合分子和相关使用方法 |
| IL325835A (en) | 2016-12-23 | 2026-03-01 | Univ Yale | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides |
| US10806737B2 (en) | 2016-12-23 | 2020-10-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides |
| US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
| UY37559A (es) * | 2017-01-06 | 2018-05-31 | Pharmacyclics Llc | Pirazolo[3,4-b]piridina y pirrolo[2,3-b]piridina como inhibidores de la tirosina quinasa de bruton |
| IL300417A (en) | 2017-01-26 | 2023-04-01 | Arvinas Operations Inc | Bifunctional benzothiophene compounds, preparations containing them and their use in therapy |
| IL319363A (en) | 2017-01-31 | 2025-05-01 | Arvinas Operations Inc | Cervalon ligands and bifunctional compounds containing them |
| EP3634960A1 (en) | 2017-06-09 | 2020-04-15 | Arvinas Operations, Inc. | Modulators of proteolysis and associated methods of use |
| EP4717317A3 (en) | 2017-06-20 | 2026-06-03 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
| WO2019023553A1 (en) | 2017-07-28 | 2019-01-31 | Arvinas, Inc. | COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF THE ANDROGEN RECEPTOR |
| EP3710002A4 (en) | 2017-11-16 | 2021-07-07 | C4 Therapeutics, Inc. | DEGRADER AND DEGRONE FOR TARGETED PROTEIN DEGRADATION |
| US11065231B2 (en) | 2017-11-17 | 2021-07-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides |
| EP3774804A1 (en) * | 2018-03-26 | 2021-02-17 | Novartis AG | N-(3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide derivatives |
| CN111936501B (zh) * | 2018-03-26 | 2023-09-22 | 诺华股份有限公司 | 布鲁顿酪氨酸激酶降解剂 |
| AU2019249849C1 (en) | 2018-04-01 | 2022-09-29 | Arvinas Operations, Inc. | BRM targeting compounds and associated methods of use |
| CA3095912A1 (en) | 2018-04-13 | 2019-10-17 | Arvinas Operations, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| WO2019204354A1 (en) | 2018-04-16 | 2019-10-24 | C4 Therapeutics, Inc. | Spirocyclic compounds |
| EP3897631A4 (en) | 2018-12-20 | 2022-11-23 | C4 Therapeutics, Inc. | TARGETED PROTEIN BREAKDOWN |
| ES2995214T3 (en) | 2019-03-06 | 2025-02-07 | C4 Therapeutics Inc | Heterocyclic compounds for medical treatment |
| KR102947433B1 (ko) | 2019-04-12 | 2026-04-06 | 씨4 테라퓨틱스, 인코포레이티드 | 이카로스 및 아이올로스의 트리시클릭 분해제 |
| EP4031247A1 (en) * | 2019-09-16 | 2022-07-27 | Novartis AG | Bifunctional degraders and their methods of use |
| US12178093B2 (en) * | 2019-09-20 | 2024-12-24 | Semiconductor Energy Laboratory Co., Ltd. | Display apparatus, display module, and electronic device |
| ES3060629T3 (en) * | 2019-10-30 | 2026-03-27 | Biogen Ma Inc | Condensed bi-heterocycles as inhibiting agents for bruton's tyrosine kinase |
| ES3055177T3 (en) * | 2019-10-30 | 2026-02-10 | Biogen Ma Inc | Condensed pyridazine or pyrimidine as btk inhibitors |
| CN116194453A (zh) | 2019-12-20 | 2023-05-30 | 卡里科生命科学有限责任公司 | 蛋白质酪氨酸磷酸酶降解剂及其使用方法 |
| EP4146655A4 (en) * | 2020-04-30 | 2024-07-31 | BeiGene, Ltd. | DEGRADATION OF BRUTON TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHOD OF USE |
-
2022
- 2022-05-05 US US18/289,438 patent/US20240287076A1/en active Pending
- 2022-05-05 WO PCT/US2022/027888 patent/WO2022235945A1/en not_active Ceased
- 2022-05-05 IL IL308219A patent/IL308219A/en unknown
- 2022-05-05 AU AU2022268977A patent/AU2022268977A1/en active Pending
- 2022-05-05 CA CA3217417A patent/CA3217417A1/en active Pending
- 2022-05-05 UY UY0001039756A patent/UY39756A/es unknown
- 2022-05-05 CN CN202280047793.5A patent/CN117580592A/zh active Pending
- 2022-05-05 JP JP2023567962A patent/JP2024519496A/ja active Pending
- 2022-05-05 AR ARP220101179A patent/AR125768A1/es unknown
- 2022-05-05 KR KR1020237041952A patent/KR20240017814A/ko active Pending
- 2022-05-05 EP EP22731839.1A patent/EP4333899A1/en active Pending
- 2022-05-05 BR BR112023023065A patent/BR112023023065A2/pt unknown
- 2022-05-05 MX MX2023013046A patent/MX2023013046A/es unknown
- 2022-05-05 TW TW111116998A patent/TW202309039A/zh unknown
-
2023
- 2023-10-31 JO JOJO/P/2023/0274A patent/JOP20230274A1/ar unknown
- 2023-11-02 CL CL2023003258A patent/CL2023003258A1/es unknown
- 2023-12-01 CO CONC2023/0016743A patent/CO2023016743A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2013266110C1 (en) | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators | |
| JP4853284B2 (ja) | チアゾール誘導体 | |
| ES2677996T3 (es) | Nuevas indazolcarboxamidas, procedimiento para su preparación, preparaciones farmacéuticas que contienen las mismas, así como su uso para la preparación de medicamentos | |
| EP1240160A1 (en) | Substituted pyridazines having cytokine inhibitory activity | |
| JP3298641B2 (ja) | イミダゾール誘導体およびそのサイトカイン阻害剤としての使用 | |
| JP2023525137A5 (enExample) | ||
| JP2022533398A5 (enExample) | ||
| JP7337813B2 (ja) | 肝再生促進又は肝細胞死の抑制もしくは防止のためのプロテインキナーゼｍｋｋ４阻害剤 | |
| AU2007225678A1 (en) | Quinolone derivative or pharmaceutically acceptable salt thereof | |
| JP2018529745A5 (enExample) | ||
| JP2010539110A5 (enExample) | ||
| CA3042684A1 (en) | Azole amides and amines as .alpha.v integrin inhibitors | |
| JP2014514302A5 (enExample) | ||
| JP2007524696A5 (enExample) | ||
| CA3055292A1 (en) | Metalloenzyme inhibitor compounds | |
| JP2023544476A5 (enExample) | ||
| RU2013154117A (ru) | Производные 1-фенил-2-пиридинилалкильных спиртов в качестве ингибиторов фосфодиэстеразы | |
| JP2025514382A5 (enExample) | ||
| JP2005504767A (ja) | ２，４，５−三置換チアゾリル誘導体およびそれらの抗炎症活性 | |
| JP2021528451A5 (enExample) | ||
| JP2022537350A5 (enExample) | ||
| JP2005508911A (ja) | 置換ピラゾールの製造方法 | |
| JP2025503995A5 (ja) | 化合物、医薬組成物、組み合わせ製品、部品キット、及びプロセス | |
| TW201418264A (zh) | 磷酸二酯酶第１０ａ型之新穎抑制劑化合物 | |
| JP2022505827A5 (enExample) |